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The C-terminus of rat L-histidine decarboxylase specifically inhibits enzymic
activity and disrupts pyridoxal phosphate-dependent interactions with
L-histidine substrate analogues
John V. FLEMING*†1, Ignacio FAJARDO‡, Michael R. LANGLOIS*, Francisca SA´NCHEZ-JIME´NEZ‡ and Timothy C. WANG*1
*University of Massachusetts Medical School, Worcester, MA 01605, U.S.A., †Institute of Molecular Medicine, University of Lisbon, Lisboa 1649-028, Portugal,
and ‡Departamento de Biolog´ıa Molecular y Bioqu´ımica, Facultad de Ciencias, Universidad de Ma´laga, Ma´laga 29071, Spain
Full-length rat HDC (L-histidine decarboxylase) translated in
reticulocyte cell lysate reactions is inactive, whereas C-terminally
truncated isoforms are capable of histamine biosynthesis. C-ter-
minal processing of the ∼ 74 kDa full-length protein occurs nat-
urally in vivo, with the production of multiple truncated isoforms.
The minimal C-terminal truncation required for the acquisition
of catalytic competence has yet to be defined, however, and it
remains unclear as to why truncation is needed. Here we show
that ∼ 74 kDa HDC monomers can form dimers, which is the
conformation in which the enzyme is thought to be catalytically
active. Nevertheless, the resulting dimer is unable to establish
pyridoxal phosphate-dependent interactions with an L-histidine
substrate analogue. Protein sequences localized to between amino
acids 617 and 633 specifically mediate this inhibition. Removing
this region or replacing the entire C-terminus with non-HDC pro-
tein sequences permitted interactions with the substrate analogue
to be re-established. This corresponded exactly with the acqui-
sition of catalytic competence, and the ability to decarboxylate
natural L-histidine substrate. These studies suggested that the
∼ 74 kDa full-length isoform is deficient in substrate binding, and
demonstrated that C-terminally truncated isoforms with mol-
ecular masses between ∼ 70 kDa and ∼ 58 kDa have gradually
increasing specific activities. The physiological relevance of our
results is discussed in the context of differential expression of
HDC isoforms in vivo.
Key words: dimer, α-fluoromethyl histidine, L-histidine de-
carboxylase, histidine methyl ester, semi-denaturing SDS/PAGE.
INTRODUCTION
In mammals, the biogenic amine histamine plays an important
role in a number of physiological processes, and while it is best
known for its function in immune and inflammation responses [1],
it has also been described as a regulator of gastric acid secretion
in the stomach [2], and of circadian rhythms in the brain [3].
Histamine-mediated signalling is not restricted to these well
described models, however, and recent studies with an HDC (L-
histidine decarboxylase) knockout mouse model [4] have pro-
vided new insights into additional roles in angiogenesis, cellular
differentiation of mast cells, and bone loss in osteoporosis [5–8].
While much is known about histamine in mammals, the dimeric
PLP (pyridoxal phosphate)-dependent enzyme that produces it,
HDC (EC 4.1.1.22) [9–11], has not been so well described.
Nevertheless, recent studies have provided new insights into the
process of histamine biosynthesis, and have identified a number
of catalytic features that are shared with other PLP-dependent
enzymes [12–15]. In the case of HDC, therefore, it is proposed that
the dimeric form of the enzyme establishes an internal aldimine
whereby the PLP cofactor is bound to the enzyme backbone.
During catalysis this bond is broken as PLP forms an external
aldimine bond with the substrate within the active site. This
allows decarboxylation of the substrate to occur. The final step in
the catalytic mechanism is breaking of the PLP–histamine bond,
leading to the release of histamine and CO2 product from the active
site, and concomitant re-establishment of the internal aldimine
bond between PLP and the enzyme backbone.
Abbreviations used: FL, FLAG; α-FMH, α-fluoromethylhistidine; GFP, green fluorescent protein; HA, haemagglutinin; HDC, histidine decarboxylase;
HME, histidine methyl ester; Ni-NTA, Ni2+-nitrilotriacetate; PLP, pyridoxal phosphate.
1 Correspondence may be sent to either author [email jfleming@fm.ul.pt (J.V.F.) or timothy.wang@umassmed.edu (T.C.W.)].
Studies that have demonstrated the dimerization and PLP-
dependence of native HDC have, for the most part, been performed
on a C-terminally truncated ∼ 54–55 kDa isoform [9–11,16]. To
our knowledge, no such studies have ever been attempted with the
full-length enzyme. Indeed, it was only after mammalian cDNAs
had been sequenced that it became apparent that the ∼ 54–55 kDa
isoform is only a processed form of the enzyme. The primary
translation product, on the other hand, has a molecular mass of
∼ 74 kDa [16–18]. This full-length isoform becomes processed
post-translationally to generate multiple C-terminally truncated
isoforms, including major ∼ 63, ∼ 58, ∼ 55 and ∼ 36 kDa iso-
forms, as well as a number of other isoforms that are less well
represented [19–22].
There are two contributing factors that help to explain why
the ∼ 74 kDa form of HDC was initially missed. First, the full-
length enzyme contains degradation-promoting elements in the
C-terminus and is extremely unstable [21–25]. Post-translational
processing removes these regions, and in over 20 years of analysis
only the processed forms of the enzyme, such as the stable ∼ 54–
55 kDa isoform described above, were purified reproducibly [9–
11]. The second reason why the full-length isoform may initially
have been overlooked relates to its apparent inactivity. There are
now a number of studies proposing that C-terminal truncation is
required for activity of HDC, and when the ∼ 74 kDa isoform
is expressed in vitro in the absence of significant processing, it is
indeed inactive [18–22]. It is understandable, therefore, that early
studies to isolate the enzyme failed to detect the full-length
isoform, given both its instability and its apparent inactivity.
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Table 1 Sequences (5′ to 3′) of oligonucleotides used for vector construction
Name of construct Sense/antisense Oligonucleotide sequence
pEP7-HA Sense gctagcgtaatacgactcactatagggcctaccggactcagatctcgagctcaagctttcgaattctgcaggtaccggatccgcgtcgacggactacaaagacgatgacgacaagtagacgcgtgcggccgc
pEP7-FL Sense gctagcgtaatacgactcactatagggcctaccggactcagatctcgagctcaagctttcgaattctgcaggtaccggatccgcgtcgacgtacccatacgatgttccagattacgctctttagacgcgtgcggccgc
pEP7-His Sense gctagcgtaatacgactcactatagggcctaccggactcagatctcgagctcaagctttcgaattctgcaggtaccggatccgcgtcgacgcatcatcatcatcatcagtaggcggccgcgggg
pEP7-HDC1/339 Antisense ccccgtcgacctgaggtagatggggttcac
pEP7-HDC1/516 Antisense atgtcgactcattgacagactccagg
pEP7-HDC1/557 Antisense ccccgtcgacttgtgcttggtggtatcgga
pEP7-HDC1/575 Antisense ccccgtcgaccgcattgtcttcttcttgttc
pEP7-HDC1/600 Antisense ccccgtcgacccatgcttcacggaagcatc
pEP7-HDC1/617 Antisense ccccgtcgacttcttcatcatcatcatttcttc
pEP7-HDC1/633 Antisense ccccgtcgacggaacactgtagaacttgat
pEP7-HDC1/656 Antisense atgtcgacaccatggcctg
pNET7 Sense ctagcatgactggtggacagcaaatgggtcgcggatcctccgcggccgctc
pNET7-HDC1/516His Sense cgcgggattggatcccatatgatggagcccagtgaatacc
Antisense gggctatccctggagtctgtcaatgagcatcatcatcatcatcattaggcggccgcgggg
The ratio of processed to unprocessed isoforms differs between
HDC-expressing tissues [19,21,22,26,27]. With such a multitude
of differentially regulated isoforms, it has proven impossible to
identify the specific isoforms that are contributing to catalysis at
any given time. Certainly we are now in a position to say that
catalysis is not dependent solely on the ∼54–55 kDa isoform,
and that isoforms smaller than ∼53 kDa in size are catalytically
inactive [22]; however, a number of processed isoforms between
∼53 and ∼74 kDa in size can be detected in the cell. Indeed,
these are the isoforms that show the greatest change in expression
during physiological regulation, and are potentially of greatest
interest [22]. The relative activities of these isoforms in the
absence of processing have not previously been established, and
the point of C-terminal truncation at which the enzyme gains
catalytic competence has yet to be defined. Considerable benefit
could be gained from identifying active and inactive isoforms
in the ∼53 to ∼74 kDa size range and, for the inactive ones,
from establishing the parameter of catalysis in which they are
deficient. This would assist in the identification of isoforms that
are theoretically capable of contributing to catalysis in vivo, and
provide important functional information regarding expression of
the enzyme.
In the present study we employed an experimental approach
that allows for the substrate-binding properties of the different
HDC isoforms to be studied. Our approach, which uses the
substrate analogues α-FMH (α-fluoromethylhistidine) and HME
(histidine methyl ester), suggests that the full-length isoform is
deficient in interacting with L-histidine substrate. We mapped the
element responsible for disrupting catalysis to between amino
acid residues 633 and 617.
MATERIALS AND METHODS
Plasmid DNA constructs
The pEP7-FL, pEP7-HA and pEP7-His constructs used in this
study were generated by cloning double-stranded oligonucleo-
tides, for which the sense strands are shown in Table 1, into the
NheI and NotI sites of the pEP-empty vector, which has already
been described [22]. For pEP7-GFP, the SalI–NotI fragments
of pEGFP-N1 was cloned into the pEP7-HA empty vector, thus
replacing the HA (haemagglutinin) tag with GFP (green fluor-
escent protein). These vectors contain CMV (cytomegalovirus)
and T7 promoter sequences upstream, and respectively FL
(FLAG), HA, 6 × His and GFP sequences downstream, from
the multiple cloning site. The HDC1/339 (i.e. HDC isoform
comprising amino acids 1–339), HDC1/516, HDC1/557, HDC1/
575, HDC1/600, HDC1/617, HDC1/633 and HDC1/656 (full-
length HDC) vector inserts were generated by PCR amplification
using the common sense primer -gggaagcttgccaccatgatggagccca-
gtgaataccgtg- and antisense primers shown in Table 1, and the
pCMV-HDC18 vector as template.
The pNET7-empty vector was generated by cloning a double-
stranded oligonucleotide, for which the sense strand is shown in
Table 1, into the NheI–BamHI sites of the pET11a vector. pNET7-
HDC1/516His was generated by cloning a PCR product amplified
using the sense and antisense primers shown in Table 1, and the
pEP7-HDC1/516HA insert as a template, into the BamHI–NotI
sites of the pNET7-empty vector.
Cell culture and transfections
For transient transfection experiments, Cos-7 cells were seeded at
a density of 1.5 × 106 cells per 100 mm dish. After 24 h the cells
were transfected with 15 µg of test or empty vector (negative)
plasmid DNA and 30 µl of Superfect reagent (Qiagen) overnight.
Lysates to be analysed for enzyme activity or for standard
immunoblotting of whole-cell lysates were harvested 24 h later
by sonication in 200 µl of 0.1 M sodium phosphate buffer
(pH 7.4). Protein concentrations were determined by the method
of Bradford [27a].
Assay of HDC activity
Activity values (measuring radiolabelled CO2 product released)
were determined from within the linear range of the activity curve
as described previously [21] using whole-cell lysates or coupled
transcription/translation reticulocyte reactions (40 µl volumes).
For transfected Cos-7 cell experiments, enzyme activities are
shown above fractionated protein samples from the same experi-
ment (means +− S.D.), and are representative of three independent
experiments.
Gel electrophoresis and immunoblot analysis
Whole-cell lysates were fractionated on denaturing (samples
containing 5% β-mercaptoethanol were boiled for 5 min; gels
and buffers contained 0.1% SDS) or semi-denaturing (gels and
buffers contained 0.1% SDS; samples were not boiled or reduced
before electrophoresis) SDS/8% (w/v)-polyacrylamide gels at
4 ◦C. Lysates to be fractionated on semi-denaturing gels were not
frozen before electrophoresis. Fractionated gels were transferred
to a PVDF membrane and exposed to autoradiographic film (for
radiolabelled protein samples) or immunoblotted by standard
c© 2004 Biochemical Society
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methods. For immunoblotting, polyclonal anti-HA antibody
(Santa Cruz) was added at a dilution of 1:150. Polyclonal anti-
HDC antibody (Accurate Chemical and Scientific), monoclonal
anti-FL antibody (Sigma) and polyclonal anti-His antibody (Santa
Cruz) were all added at a dilution of 1:1000. All gels or immuno-
blots shown are representative of three independent experiments.
Coupled transcription/translation reactions
In vitro transcription/translation reactions were performed using
rabbit reticulocyte lysates with 1 µg of test or empty vector
(negative) plasmids and were supplemented with radiolabelled
(for gel fractionation) or unlabelled (for enzyme assays) methio-
nine as advised (Promega; TNT-Quick kit). Reactions were
supplemented with PLP (0.1 mM) or α-FMH (Sigma; 1.0 µM
or 1.0 mM) where appropriate. For enzyme assays, 35 µl
of 0.1 M sodium phosphate buffer (pH 7.4), supplemented
with the translation inhibitor cycloheximide, was added (final
concentration 20 µg/ml) to TNT reactions. All activities shown are
means +− S.D. (n = 3 reactions). For denaturing and non-reducing
SDS/PAGE, 2 µl of reaction mixture was fractionated on 8% gels.
All gels shown are representative of three independent reactions.
Purification of His-tagged proteins expressed in reticulocyte
cell lysate reactions
The His-tagged proteins HDC1/516–His and HDC1/656–His were
expressed from the expression vectors pEP7-HDC1/516His
and pEP7-HDC1/656His respectively in reticulocyte cell lysate
reactions as described above. Following completion of the re-
action and the addition of cycloheximide, His-tagged proteins
were batch-purified by binding for 1 h to Ni-NTA (Ni2+-nitrilo-
triacetate)–agarose beads (Qiagen) prewashed with buffer B
(0.1 M sodium phosphate buffer, 50 mM NaCl, 0.1 mM PLP,
pH 7.4). Beads were washed once with buffer B and eluted with
50 mM EDTA in 50 µl of buffer B. Eluted protein was split into
four aliquots and incubated for 1 h with α-FMH, HME (Sigma)
or L-histidine (Sigma) as described above, before fractionation on
semi-denaturing and denaturing SDS/polyacrylamide gels.
Purification of recombinant HDC1/516–His from bacteria
Escherichia coli BL21 (DE3) LysS cells, transformed with the
pNET7-HDC1/516His vector, were grown until the attenuance
(D600) reached 0.4, and then induced with 1 mM isopropyl β-D-
thiogalactoside for 5 h at 37 ◦C. Cells were lysed by sonication
in 0.1 M sodium phosphate buffer (pH 7.4) containing 0.1 mM
PLP and 150 mM NaCl (buffer A) plus 2 mM imidazole. His-
tagged protein was purified by batch purification over Ni-NTA
beads as advised by the manufacturer (Qiagen), and washed three
times with buffer A/40 mM imidazole. The column was washed
two more times with buffer A (no imidazole), and protein was
finally eluted with buffer A containing 50 mM EDTA. Aliquots
of 500 µl of purified extracts were dialysed overnight at 4 ◦C
against 5 litres of buffer containing 0.1 M sodium phosphate,
0.1 mM PLP and 1 mM dithiothreitol (molecular mass cut-off
35 kDa). The protein concentration was determined by the method
of Bradford [27a], and 200 µg fractions were used for SDS/PAGE.
When appropriate, samples were incubated with α-FMH, HME or
L-histidine for 1 h.
Co-immunoprecipitation of HDC monomer generated
in reticulocyte cell lysates
pEP7-HDC1/656HA was used as template in a reticulocyte cell
lysate reaction in the presence of non-radiolabelled methionine
as described above. Expressed protein was immunoprecipitated
using an anti-HA antibody and Protein A–Sepharose beads using
previously described methods [22], except that buffer C (0.1 M
sodium phosphate, pH 7.4, 1.0 mM PLP, 150 mM NaCl, 0.1%
Triton X-100) was used for antibody incubation and washing
steps. Immunoprecipitated, HA-tagged protein was resuspended
in 30 µl of buffer C, and subsequently divided into two fractions
and incubated for 2 h with either radiolabelled GFP or radio-
labelled HDC1/656–FL, which had been expressed in reticulocyte
cell lysate reactions in the presence of 35S-labelled methionine
using the pEP7-GFP and pEP7-HDC1/656FL vectors as temp-
lates. The HA-tagged protein HDC1/656–HA was re-precipitated
and washed multiple times in buffer A. Samples were fractionated
on denaturing SDS/polyacrylamide gels and transferred to PVDF
membranes. Membranes were dried and exposed to autoradio-
graphic film to test for the co-immunoprecipitation of radiolabel-
led proteins, and subsequently used for immunoblotting with an
anti-HA antibody to confirm equal immunoprecipitation of bait
HDC1/656–HA protein.
RESULTS
The full-length HDC1/656 isoform is processed into multiple
isoforms in vivo and is inactive when expressed in vitro
Post-translational processing of full-length rat HDC results in
the production of a number of different sized isoforms. This is
shown in Figure 1(A), where transient transfection of Cos-7 cells
with pEP7-HDC1/656HA resulted in enzymic activity (Figure 1A,
upper panel). However, due to the fact that post-translational
processing of the primary translation product resulted in the
production of numerous isoforms, it was not immediately apparent
which isoforms were responsible for activity (Figure 1A, lower
panel).
In reticulocyte cell lysate reactions, and in the absence of visible
processing, the full-length isoform was inactive, and C-terminal
truncation was required for activity (Figure 1B). Excessive trun-
cation also inactivated the enzyme, however, and a ∼36 kDa
isoform (HDC1/339–HA), similar to that produced by in vivo
processing in Cos-7 cells (Figure 1A), similarly lacked activity
(Figure 1B).
The substrate analogues HME and α-FMH could theoretically be
used to determine the catalytic stage in which the full-length HDC
isoform is deficient
We wanted to understand better why the full-length HDC isoform
is inactive and in what parameter of catalysis it is deficient. Three
hypotheses were initially considered: first, that the C-terminus
somehow acts to block interactions with the substrate and form-
ation of the external aldimine with PLP; secondly, that substrate
binding occurs, but there is an inability to decarboxylate the ex-
ternal aldimine within the active site; or thirdly, that substrate
binding and decarboxylation occur, but the histamine and CO2
products fail to be released from the active site. Deficiencies
in any of these steps could explain the apparent necessity for
truncation.
Substrate analogues of L-histidine have been described that
block the reaction at different catalytic stages [14,26–35]. It was
proposed that exploiting the differential inhibition properties of
these analogues might make it possible to determine the catalytic
step at which the full-length HDC isoform is deficient. Scheme 1
highlights the basic features of this approach, with Scheme 1(A)
showing the normal decarboxylation reaction when the substrate
L-histidine is used, with the release of CO2 and histamine
c© 2004 Biochemical Society
772 J. V. Fleming and others
Figure 1 In the absence of post-translational processing, the ∼74 kDa HDC primary translation product is inactive
(A) Cos-7 cells were transfected with the pEP7-HA empty (−ve) or pEP7-HDC1/656HA vector. Lysates were analysed for HDC activity (upper panel; means +− S.D.) or fractionated for immunoblotting
with an anti-HDC antibody (lower panel). Molecular-mass markers are shown on the left. Major and minor arrows on the right correspond to HDC immunoreactive bands. (B) pEP7-HA empty
(−ve), pEP7-HDC1/339HA, pEP7-HDC1/516HA and pEP7-HDC1/656HA vectors were used as templates in coupled transcription/translation reactions. Unlabelled expression reaction products
were analysed for enzyme activity (upper panel; means +− S.D.). 35S-radiolabelled reaction products were fractionated on denaturing SDS/polyacrylamide gels (lower panel).
products. When the enzyme-activated inhibitor α-FMH is used,
decarboxylation of the analogue also occurs (Scheme 1B). In this
case, however, the decarboxylated intermediates that are produced
bind covalently to the enzyme backbone to inhibit the enzyme
irreversibly [28,29,36–38]. Our enzyme assay, which measures
the release of radiolabelled CO2 product, shows that product is
not being released from the active site of the full-length enzyme. If
we could demonstrate that catalytic intermediates of α-FMH are
nevertheless accumulating in the active site, this might indicate
that the full-length isoform is capable of decarboxylating the
substrate, but is specifically deficient in product release.
In contrast, the substrate analogue HME has been well de-
scribed to enter the active site and form an external aldimine with
PLP, but, unlike α-FMH, it is not decarboxylated (Scheme 1C).
Catalytic intermediates produced from this analogue act to inhibit
the enzyme reversibly, and their accumulation within the active
site can be used as a measure of substrate binding and an ability
to form the external aldimine, but does not reflect an ability to
decarboxylate [15,33,39]. If we could demonstrate that catalytic
intermediates of HME accumulate in the active site of the full-
length enzyme, but that intermediates from α-FMH do not, this
would indicate that the primary translation product is deficient
specifically in decarboxylation.
Substrate analogues alter the electrophoretic mobility of
recombinant HDC1/516, indicative of the accumulation
of catalytic intermediates
The binding of substrate analogues within the active site alters the
absorption spectrum properties of the PLP cofactor. Ideally,
therefore, we would use highly purified extracts of recombinant
full-length enzyme to study spectrophotometric properties in the
presence and absence of the two substrate analogues α-FMH
and HME. However, in accordance with previous studies, we
experienced difficulties in isolating full-length rat HDC, with in-
sufficient material recovered to allow for classical biochemical or
biophysical analysis [15,24,39]. Nevertheless, it has recently been
demonstrated [40] that the accumulation of HME and α-FMH
intermediates within the active site alters the fractionation pro-
perties of an HDC isoform on semi-denaturing polyacrylamide
gels. This is shown in Figure 2(A), where there is a clear change
in fractionation properties after incubation of partially purified
recombinant HDC1/516–His with α-FMH and HME. No change
was observed when the native L-histidine substrate was used (lane
labelled ‘His’ in Figure 2A), indicating that rapid decarboxyl-
ation was occurring without the accumulation of intermediates.
While the exact molecular basis for each of the bands observed
has yet to be characterized fully, the changes in electrophoretic
mobility observed can nevertheless be used as an indicator of
successful interactions with the respective substrate analogues.
This approach has only ever been shown for purified fractions
of recombinant enzyme, however, and as already mentioned,
we were unable to purify sufficient quantities of the full-length
enzyme to perform such an analysis. Nevertheless, we wondered
whether it would be possible to detect changes in the electro-
phoretic mobility of proteins in a heterogeneous mixture, such as
the reticulocyte cell lysate reactions used in Figure 1(B).
To test for this, we expressed the active HDC1/516–FL protein
in reticulocyte cell lysate reactions in the presence of α-FMH.
This treatment inhibited the enzyme (Figure 2B, top panel).
When lysates were electrophoresed on semi-denaturing gels, the
pattern of fractionation was slightly different from that observed
for the purified fractions in Figure 2(A), in as much as higher-
molecular-mass bands were also observed in the absence of α-
FMH (see Figure 2B, middle panel, Control lane). Nevertheless,
the incubation of expressed protein with α-FMH still resulted in
a change in the pattern of electrophoretic mobility (Figure 2B,
middle panel, compare Control and αFMH lanes). Denaturing
c© 2004 Biochemical Society
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Scheme 1 L-Histidine substrate analogues inhibit HDC enzyme activity at different catalytic stages
Scheme for the reaction of HDC with L-histidine (A), α-FMH (B) and HME (C). See [40] for further details.
SDS/PAGE (Figure 2B, lower panel) confirmed that only a single
radiolabelled protein was being expressed in the reticulocyte
reactions, so it is quite possible that some of the extra bands
observed on the semi-denaturing gels were representative of inter-
actions with other reticulocyte cell proteins. Nevertheless, they
did not prevent the detection of interactions between the substrate
analogue and the enzyme.
Although the mechanism of action of α-FMH has been well
described [13,15,28,29,39], we needed to be sure that the changes
observed for the enzyme in reticulocyte cell lysates related
specifically to the active site. Given that HDC-mediated catalysis
depends on PLP, it made sense also to determine whether changes
in electrophoretic mobility were influenced by concentrations of
the specific active-site cofactor, and reactions were supplemented
with 1.0 mM PLP (see Figure 2B, middle panel, right-hand
lane). This treatment strongly promoted the observed changes
in electrophoretic mobility associated with α-FMH, and involved
the clear recruitment of protein from the lower-molecular-mass
band.
Together, these studies indicated a specific relationship between
HDC expressed in reticulocyte cell lysates, the substrate analogue
α-FMH, the active-site cofactor PLP, and a change in electro-
phoretic mobility detectable on semi-denaturing gels.
α-FMH does not alter the electrophoretic mobility of the
full-length HDC1/656 isoform
In the previous sections, we detected interactions between the
HDC enzyme and a substrate analogue in a heterogeneous
experimental model. We wished to use this approach to test the
ability of full-length HDC to interact with the α-FMH substrate
analogue. Truncated HDC1/516–HA and full-length HDC1/656–
HA were expressed in reticulocyte cell lysate reactions in
both the presence and the absence of α-FMH. Radiolabelled
reaction products were fractionated on semi-denaturing and
denaturing SDS/polyacrylamide gels (Figure 2C, upper and lower
panels respectively). In contrast with the HDC1/516–HA isoform,
incubation of HDC1/656–HA with α-FMH had no effect
on electrophoretic properties under semi-denaturing conditions
(Figure 2C, upper panel, compare two right-hand lanes).
Specific C-terminal sequences block interactions
with the substrate analogue
We wondered how specific this effect is. For example, was the
effect associated with particular amino acid sequences encoded
by the C-terminal tail of HDC, or would the presence of non-HDC
protein sequences placed at this location in the enzyme also inhibit
c© 2004 Biochemical Society
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Figure 2 Semi-denaturing gels can be used to test interactions between HDC isoforms and L-histidine substrate analogues
(A) Samples of 200 µg of recombinant HDC1/516–His were incubated in the absence (Control) or presence of 1 mM α-FMH, 20 mM L-histidine (His) or 20 mM HME for 1 h. Lysates were
fractionated on semi-denaturing (upper panel) or denaturing (lower panel) SDS/polyacrylamide gels for immunoblotting with an anti-HDC antibody. Arrow B highlights changes in electrophoretic
mobility in the presence of substrate analogues. (B) pEP7-HDC1/516L was used as template in coupled transcription/translation reactions in the presence or absence of 1.0 mM α-FMH and 1.0 mM
PLP as indicated. Reactions were not supplemented with PLP except where indicated. Unlabelled reaction products were used to determine enzyme activity. Products from radiolabelled reactions
performed in parallel were fractionated on semi-denaturing (middle panel) or denaturing (lower panel) SDS/polyacrylamide gels. ‘−ve’ denotes reactions where the pEP7-FL empty vector was used as
template. (C) pEP7-HDC1/516HA and pEP7-HDC1/656HA vectors were used as templates in coupled transcription/translation reactions in the presence or absence of 1.0 mM α-FMH as indicated.
All reactions were supplemented with 1.0 mM PLP. Radiolabelled reaction products were fractionated on semi-denaturing (upper panel) or denaturing (lower panel) SDS/polyacrylamide gels.
the interaction with α-FMH? We have recently demonstrated that
HDC1/477 is the minimal unit of C-terminally truncated HDC
that retains catalytic activity, and that residues 478–656 of the
protein sequence of HDC are not required for catalysis [22]. We
removed this non-essential domain and generated a chimaeric
protein in which the specific HDC residues 478–656 (∼20 kDa)
were replaced by GFP (∼27 kDa). The chimaeric HDC1/477–
GFP protein was expressed in coupled transcription/translation
reactions in the presence and absence of α-FMH, and reaction
products were fractionated on semi-denaturing gels. These studies
showed that replacing the C-terminal sequence of HDC with a
non-specific GFP sequence restored the ability of HDC to interact
with α-FMH, and resulted in altered electrophoretic mobility of
the HDC1/477–GFP isoform (Figure 3A, upper panel, lanes 2
and 3). These studies demonstrated that sequences in the C-
terminus of HDC act specifically to compromise interactions
with the α-FMH substrate analogue (compare with Figure 3A,
lanes 5 and 6). Restoring the ability of HDC1/477–GFP to
interact with the substrate analogue also corresponded exactly
with its ability to bind and decarboxylate the real L-histidine
substrate. The HDC1/477–GFP chimaera had enzymic activity
levels comparable with those of HDC1/516–HA in Figure 1(B)
(results not shown).
C-terminal truncation between amino acid residues 633 and 617
allows interactions with the substrate analogue to be established
These data demonstrated for the first time that the C-terminus
contains specific sequences that disrupt HDC-mediated catalysis,
and localized the inhibitory domain in a very general manner to
the region of the protein comprising residues 478–656. We wanted
to determine more specifically what sequences are involved,
and to identify the minimal C-terminal truncation that is required
to remove the block. We also wanted to study the manner (gradual
or immediate) in which decarboxylation competence is acquired.
A series of C-terminally truncated isoforms was generated and
expressed in reticulocyte cell lysate reactions in the presence
and absence of α-FMH. Radiolabelled reaction products were
fractionated on semi-denaturing gels. The electrophoretic mobi-
lity of the HDC1/656–HA and HDC1/633–HA isoforms was
unaltered by the substrate analogue (Figure 3B). The HDC1/617–
HA isoform, on the other hand, and all subsequent truncated
isoforms, exhibited a change in electrophoretic mobility in
response to interactions with the analogue. For the HDC1/617–
HA isoform this change was quite weak and indicated a gradual
transition to being able to interact with the analogue. Gradually
acquiring the ability to interact with α-FMH coincided exactly
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Figure 3 Specific sequences in the C-terminus of HDC inhibit interactions with the substrate analogue α-FMH
(A) pEP7-HDC1/477GFP and pEP7-HDC1/656HA vectors were used as templates in coupled transcription/translation reactions in the presence or absence of 1.0 mM α-FMH as indicated.
All reactions were supplemented with 1.0 mM PLP. Radiolabelled reaction products were fractionated on semi-denaturing (upper panel) or denaturing (lower panel) SDS/polyacrylamide gels.
‘−ve’ denotes reactions where the pEP7-HA empty vector was used as template. (B) pEP7-HDC1/516HA, pEP7-HDC1/557HA, pEP7-HDC1/575HA, pEP7-HDC1/617HA, pEP7-HDC1/633HA and
pEP7-HDC1/656HA vectors were used as templates in parallel transcription/translation reactions in the presence or absence of 1.0 mM α-FMH as indicated. All reactions were supplemented with
1.0 mM PLP. Radiolabelled reaction products were fractionated as described for (A). (C) pEP7-HDC1/516HA, pEP7-HDC1/575HA, pEP7-HDC1/600HA, pEP7-HDC1/617HA, pEP7-HDC1/633HA
and pEP7-HDC1/656HA vectors were used as template in parallel transcription/translation reactions as indicated. All reactions were supplemented with 1.0 mM PLP. Unlabelled expression reaction
products were analysed for enzyme activity (upper panel; mean +− S.D.). Radiolabelled reaction products expressed in parallel were fractionated on denaturing SDS/polyacrylamide gels to ensure
equal expression of samples.
with progressive acquisition of catalytic activity in enzyme assays
(Figure 3C).
C-terminal sequences also disrupt interactions with the substrate
analogue HME
These data suggested that the full-length isoform of HDC is
unable to accumulate decarboxylated intermediates of α-FMH,
and identified the specific sequences that appear to be responsible
for this. Next, we wanted to determine whether this reflected
an inability to bind the substrate and form an external aldimine
within the active site, as might be indicated by whether or
not the protein is capable of interacting with the substrate
analogue HME (Scheme 1C). Thus far, our experiments with
reticulocyte cell lysates were performed by adding α-FMH
directly. When HME was added to active HDC1/516–HA under
similar experimental conditions, however, there was no effect
on electrophoretic mobility. Our studies with the recombinant
protein HDC1/516–His (Figure 2A) indicated that this active
form of the enzyme should indeed interact with HME. We
wondered, therefore, whether this apparent inconsistency with the
heterogeneous lysates was a reflection of the irreversible versus
reversible inhibition properties of α-FMH and HME respectively.
Reticulocyte cell lysate reactions contain free L-histidine for
protein synthesis, and thus would be expected to reversibly
displace any intermediates of the HME analogue that accumulated
in the active site. Decarboxylated intermediates of α-FMH, on
the other hand, would not be affected in this way. To test for this,
we expressed the His-tagged HDC1/516–His and HDC1/656–His
isoforms in the reticulocyte cell lysates. The His-tagged proteins
were pulled down with Ni-NTA–agarose beads and washed once
with a low-stringency sodium phosphate buffer to remove excess
histidine. After elution from the beads with EDTA (as opposed to
imidazole), HDC isoforms were incubated with HME for 1 h and
fractionated on semi-denaturing gels. It was immediately apparent
that the mobility of the active HDC1/516–His isoform was
changed by this treatment (Figure 4A, upper panel, HME lane).
In contrast, that of the full-length isoform was not (Figure 4B,
upper panel, HME lane). The full-length primary translation pro-
duct thus appears to be deficient in binding of substrate and form-
ation of the external aldimine.
The full-length HDC isoform is capable of homodimerization
Thus far, we had worked to identify steps in the catalytic
reaction that the full-length HDC isoform was unable to perform.
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Figure 4 The C-terminus of HDC inhibits interactions with the substrate
analogue HME
pEP7-HDC1/516His (A) and pEP7-HDC1/656His (B) vectors were used as templates in coupled
transcription/translation reactions. After completion of the reaction, proteins were bound to Ni-
NTA–agarose beads and partially purified to remove L-histidine, as described in the Materials and
methods section. Samples were divided into four and treated for 1 h with 1 mM α-FMH, 20 mM
HME or 20 mM L-histidine (His) as indicated. Radiolabelled reaction products were fractionated
on semi-denaturing (upper panels) or denaturing (lower panels) SDS/polyacrylamide gels. ‘−ve’
denotes reactions where the pEP7-His empty vector was used as template.
Having demonstrated that it was deficient in the most basic step
of substrate binding to PLP in the active site, we wondered
whether this in fact reflected an inability of the full-length
isoform to dimerize. The dimerization properties of HDC iso-
forms have not been well studied, and the possibility that C-
terminal sequences might disrupt monomer interactions has not
adequately been addressed. To test this hypothesis, unlabelled
HDC1/656–HA was expressed in reticulocyte cell lysates in the
presence of non-radiolabelled methionine. HA-tagged protein was
immunoprecipitated with an anti-HA antibody and Protein
A–Sepharose, and incubated subsequently with radiolabelled
HDC1/656–FL or radiolabelled GFP. HA-tagged protein was re-
precipitated and fractionated to look for co-immunoprecipitation.
A specific radioactive HDC1/656–FL band was detected, and
demonstrated that the full-length isoform is indeed capable of
forming specific homodimers (Figure 5, upper panel, right lane).
Thus the C-terminus of HDC does not disrupt dimerization. The
observed deficiencies in catalysis therefore do not appear to be
associated with the tertiary arrangement of monomers, but with
the catalytic and substrate-binding mechanism of the enzyme.
DISCUSSION
Our primary objective at the outset of this study was to understand
why C-terminal truncation appears to be required for the enzymic
activity of HDC, and to identify the parameter of catalysis in
which the full-length isoform is deficient. Hypotheses relating
to the dimerization, substrate binding, substrate decarboxylation
and product release properties of the enzyme were proposed and
tested. The results from these studies lead us to believe that the
Figure 5 The HDC primary translation product is capable of homo-
dimerization
Non-radiolabelled HDC1/656–HA, bound to Protein A–Sepharose beads via an anti-HA antibody,
was incubated for 2 h with radiolabelled GFP (left lane) or radiolabelled HDC1/656–FL (right
lane). HA-tagged HDC1/656–HA was immunoprecipitated (IP) and washed. Samples were
fractionated on denaturing SDS/polyacrylamide gels and transferred to a PVDF membrane.
Membranes were exposed to autoradiographic film to test for the co-immunoprecipitation of
radiolabelled proteins (upper panel), and subsequently immunoblotted (IB) with an anti-HA
antibody to confirm equal immunoprecipitation of bait HDC1/656–HA protein (lower panel).
full-length isoform is dimerization-competent, but that specific
sequences located primarily between residues 617 and 633 (but
extending through to residue 600) act to disrupt interactions with
substrate and substrate analogues.
These studies would ideally have been performed using homo-
geneous preparations of purified protein; however, purification
of the full-length isoform from native sources is notoriously
difficult. The low abundance of HDC-expressing cells, coupled
with the instability of the full-length isoform, suggests that it will
always be problematic to purify the ∼74 kDa isoform in this way,
not just on account of its instability, but also on account of its
apparent lack of solubility [15,24,39]. Attempts to overexpress
and isolate the full-length mammalian enzyme from bacteria
as part of the present study also failed repeatedly (HDC1/656
isoforms with N- or C-terminal glutathione S-transferase or
C-terminal 6 × His tags; results not shown). In each case the
quantities of soluble protein recovered were insufficient, and while
it was possible to increase this amount by employing chemical
detergents, these conditions additionally inactivated the active
C-terminally truncated HDC1/516–His isoform described in
Figure 2(A), which was always expressed and purified in parallel.
It became increasingly apparent, therefore, that it would not be
possible to study the dimerization, substrate binding and product
release properties of the full-length isoform if we continued to
depend solely on homogeneous preparations, and the traditional
biochemical and biophysical approaches. We therefore chose to
work with a reticulocyte cell lysate model, where solubility and
stability were less of a problem, and in the absence of signi-
ficant post-translational processing we would still be able to
study the endogenous catalytic properties of expressed isoforms.
It was relatively straightforward with this model, therefore, to
demonstrate the dimerization properties of ∼74 kDa monomers
of HDC, but we also needed to employ methodologies that allowed
c© 2004 Biochemical Society
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interactions with the substrate analogues HME and α-FMH
to be detected in a heterogeneous protein environment. It was
possible to detect these interactions by monitoring changes in
electrophoretic mobility under semi-denaturing fractionation con-
ditions. We specifically demonstrated that the observed changes,
which were robust and highly reproducible, were indicative of
interactions with the PLP cofactor within the active site.
The exact molecular basis for all of the bands observed on the
semi-denaturing gels remains unclear. Nevertheless, the molecu-
lar interactions of HME and α-FMH with active HDC isoforms
have been well described, and the observed changes in electro-
phoretic mobility occurred only when these substrate analogues
were used. Specific L-dopa analogues that inhibit the related
dopa decarboxylase enzyme had no effect. Furthermore, not
only were interactions not observed with the inactive full-length
HDC isoform, but, in experiments to truncate or replace the
C-terminus (Figure 3), restoring the ability to interact with a
substrate analogue coincided exactly with the ability to bind and
decarboxylate the native L-histidine substrate.
Employing this approach to study the catalytic properties of
different HDC isoforms, and identifying the catalytic parameter
in which the full-length isoform appears to be deficient, underlines
the use and simple applicability of this novel approach. The
relevance of this method for studying catalytically competent
isoforms in heterogeneous tissue samples, and the potential to
identify the isoforms that are binding substrate under different
physiological conditions, is self-evident. In relation to the present
study, however, a number of our observations are particularly
noteworthy. For example, we demonstrated that specific HDC
protein sequences in the C-terminus inhibit interactions with the
substrate analogue. The manner in which interactions with sub-
strate analogues are acquired slowly is, we believe, informative,
and has important physiological implications. For example, the
progressive acquisition of activity as the enzyme is C-terminally
truncated is possibly suggestive of the unwinding of a relatively
large inhibitory element, such as a helix or other secondary struc-
ture. This in contrast with truncation of the enzyme between
residues 477 and 472, which results in the immediate and absolute
loss of activity [22]. Therefore, while we are now in a position to
state that HDC isoforms of between 70 kDa and 54 kDa contain
endogenous activity, the specific activities of isoforms that retain
some of the inhibitory structure between residues 633 and 575
are comparatively low. The ∼63 kDa isoform, whose expression
in rat stomach is regulated during feeding, is a case in point
[22], and the changes in isoform expression that occur during
physiological regulation need not necessarily be proportional to
changes in enzymic activity.
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